Brief: Sprint Bioscience Q1 Operating Loss Widens To SEK 13.0 Mln
May 12 (Reuters) - Sprint Bioscience AB SPRINT.ST :
* Q1 NET SALES AMOUNTED TO SEK 0 (5.4) MILLION
* Q1 OPERATING PROFIT AMOUNTED TO SEK -13.0 (-9.5) MILLION
* Q1 PROFIT AFTER TAX AMOUNTED TO SEK -13.7 (-9.8) MILLION
* OUTLOOK 2021: NO FORECAST IS PROVIDED
Source text for Eikon: ID:nWkr7lb5hl
Further company coverage: SPRINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln